Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 799 GBX -0.55% Market Closed
Market Cap: 4B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Intrinsic Value

The intrinsic value of one HIK stock under the Base Case scenario is 3 721.06 GBX. Compared to the current market price of 1 799 GBX, Hikma Pharmaceuticals PLC is Undervalued by 52%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HIK Intrinsic Value
3 721.06 GBX
Undervaluation 52%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Hikma Pharmaceuticals PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for HIK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about HIK?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Hikma Pharmaceuticals PLC

Provide an overview of the primary business activities
of Hikma Pharmaceuticals PLC.

What unique competitive advantages
does Hikma Pharmaceuticals PLC hold over its rivals?

What risks and challenges
does Hikma Pharmaceuticals PLC face in the near future?

Summarize the latest earnings call
of Hikma Pharmaceuticals PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Hikma Pharmaceuticals PLC.

Provide P/S
for Hikma Pharmaceuticals PLC.

Provide P/E
for Hikma Pharmaceuticals PLC.

Provide P/OCF
for Hikma Pharmaceuticals PLC.

Provide P/FCFE
for Hikma Pharmaceuticals PLC.

Provide P/B
for Hikma Pharmaceuticals PLC.

Provide EV/S
for Hikma Pharmaceuticals PLC.

Provide EV/GP
for Hikma Pharmaceuticals PLC.

Provide EV/EBITDA
for Hikma Pharmaceuticals PLC.

Provide EV/EBIT
for Hikma Pharmaceuticals PLC.

Provide EV/OCF
for Hikma Pharmaceuticals PLC.

Provide EV/FCFF
for Hikma Pharmaceuticals PLC.

Provide EV/IC
for Hikma Pharmaceuticals PLC.

Show me price targets
for Hikma Pharmaceuticals PLC made by professional analysts.

What are the Revenue projections
for Hikma Pharmaceuticals PLC?

How accurate were the past Revenue estimates
for Hikma Pharmaceuticals PLC?

What are the Net Income projections
for Hikma Pharmaceuticals PLC?

How accurate were the past Net Income estimates
for Hikma Pharmaceuticals PLC?

What are the EPS projections
for Hikma Pharmaceuticals PLC?

How accurate were the past EPS estimates
for Hikma Pharmaceuticals PLC?

What are the EBIT projections
for Hikma Pharmaceuticals PLC?

How accurate were the past EBIT estimates
for Hikma Pharmaceuticals PLC?

Compare the revenue forecasts
for Hikma Pharmaceuticals PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Hikma Pharmaceuticals PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Hikma Pharmaceuticals PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Hikma Pharmaceuticals PLC compared to its peers.

Compare the P/E ratios
of Hikma Pharmaceuticals PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Hikma Pharmaceuticals PLC with its peers.

Analyze the financial leverage
of Hikma Pharmaceuticals PLC compared to its main competitors.

Show all profitability ratios
for Hikma Pharmaceuticals PLC.

Provide ROE
for Hikma Pharmaceuticals PLC.

Provide ROA
for Hikma Pharmaceuticals PLC.

Provide ROIC
for Hikma Pharmaceuticals PLC.

Provide ROCE
for Hikma Pharmaceuticals PLC.

Provide Gross Margin
for Hikma Pharmaceuticals PLC.

Provide Operating Margin
for Hikma Pharmaceuticals PLC.

Provide Net Margin
for Hikma Pharmaceuticals PLC.

Provide FCF Margin
for Hikma Pharmaceuticals PLC.

Show all solvency ratios
for Hikma Pharmaceuticals PLC.

Provide D/E Ratio
for Hikma Pharmaceuticals PLC.

Provide D/A Ratio
for Hikma Pharmaceuticals PLC.

Provide Interest Coverage Ratio
for Hikma Pharmaceuticals PLC.

Provide Altman Z-Score Ratio
for Hikma Pharmaceuticals PLC.

Provide Quick Ratio
for Hikma Pharmaceuticals PLC.

Provide Current Ratio
for Hikma Pharmaceuticals PLC.

Provide Cash Ratio
for Hikma Pharmaceuticals PLC.

What is the historical Revenue growth
over the last 5 years for Hikma Pharmaceuticals PLC?

What is the historical Net Income growth
over the last 5 years for Hikma Pharmaceuticals PLC?

What is the current Free Cash Flow
of Hikma Pharmaceuticals PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Hikma Pharmaceuticals PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Hikma Pharmaceuticals PLC

Current Assets 2.3B
Cash & Short-Term Investments 260m
Receivables 965m
Other Current Assets 1.1B
Non-Current Assets 2.6B
Long-Term Investments 63m
PP&E 1.1B
Intangibles 1.1B
Other Non-Current Assets 268m
Current Liabilities 1.4B
Accounts Payable 541m
Short-Term Debt 79m
Other Current Liabilities 760m
Non-Current Liabilities 1.2B
Long-Term Debt 1.1B
Other Non-Current Liabilities 120m
Efficiency

Earnings Waterfall
Hikma Pharmaceuticals PLC

Revenue
3B USD
Cost of Revenue
-1.6B USD
Gross Profit
1.4B USD
Operating Expenses
-813m USD
Operating Income
617m USD
Other Expenses
-332m USD
Net Income
285m USD

Free Cash Flow Analysis
Hikma Pharmaceuticals PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Hikma Pharmaceuticals reported robust performance across all divisions. Injectables showed significant growth, despite additional costs, with successful launches of unique 505(b)(2) products. Europe and MENA regions performed exceedingly well, with MENA overcoming currency challenges in Egypt and Sudan to achieve nearly 17% growth. Oncology tenders contributed to high profitability, and despite a mixed drug pricing environment, volumes increased leading to an uptick in demand. The company is optimistic, as FDA inspections of competitors may result in further market opportunities. Hikma's cash flow remains strong and the company is well-poised for future success.

What is Earnings Call?
Fundamental Scores

HIK Profitability Score
Profitability Due Diligence

Hikma Pharmaceuticals PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive Operating Income
Positive 3-Years Revenue Growth
58/100
Profitability
Score

Hikma Pharmaceuticals PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

HIK Solvency Score
Solvency Due Diligence

Hikma Pharmaceuticals PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Average Altman Z-Score
51/100
Solvency
Score

Hikma Pharmaceuticals PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HIK Price Targets Summary
Hikma Pharmaceuticals PLC

Wall Street analysts forecast HIK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HIK is 2 386.34 GBX with a low forecast of 2 020 GBX and a high forecast of 3 024 GBX.

Lowest
Price Target
2 020 GBX
12% Upside
Average
Price Target
2 386.34 GBX
33% Upside
Highest
Price Target
3 024 GBX
68% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for HIK?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for HIK is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC

Country

United Kingdom

Industry

Pharmaceuticals

Market Cap

4B GBP

Dividend Yield

4.39%

Description

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The firm is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The firm operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. The company also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.

Contact

London
1 New Burlington Place
+442073992760.0
www.hikma.com

IPO

2005-11-01

Employees

8 703

Officers

Executive Chairman
Engineer Said Samih Taleb Darwazah
CEO & Director
Mr. Riad Ali Mishlawi
Executive Vice Chairman & President of MENA
Mr. Mazen Samih Taleb Darwazah
Chief Financial Officer
Mr. Khalid Waleed Hosny Al Nabilsi
Chief Information Officer
Patricia Bousfield
Associate Director of Investor Relations
Mr. Guy Featherstone
Show More
General Counsel
Mr. Samuel Park
Executive Vice President of Corporate Development and M&A
Mr. Bassam Wael Rushdi Kanaan CFA, CPA
Chief People Officer
Mr. Hussein Omar Arkhagha
Executive Vice President of Strategic Planning & Global Affairs
Ms. Susan Ringdal
Show Less

See Also

Discover More
What is the Intrinsic Value of one HIK stock?

The intrinsic value of one HIK stock under the Base Case scenario is 3 721.06 GBX.

Is HIK stock undervalued or overvalued?

Compared to the current market price of 1 799 GBX, Hikma Pharmaceuticals PLC is Undervalued by 52%.

Back to Top